[16] Chen Jeffrey,Vaughan Victoria Claire,Matisko M o rg a n , e t a l . R e t i c u l a r P a t c h e s i n a P a t i e n t Wi t h Multiple Myeloma: Answer[J]. The American Journal of Dermatopathology,2022,44(9)：700-701.
[17] Weiss Stephen,Mapara Markus,Lentzsch Suzanne，etal. The role of checkpoint inhibitor PD-1H/VISTA in osteoclast activation and bone disease in multiple myeloma[J]. Clinical Lymphoma, Myeloma and Leukemia,2022,22(S)：15-15.
[18] Wan Yike,Chen Mengping,Li Xin,etal.Singlecell RNA-seq reveals XBP1-SLC38A2 axis as a player in immunosuppressive T lymphocytes in multiple myeloma[J]. Clinical Lymphoma, Myeloma and Leukemia,2022,22(S)：18-18.
[19] Slade Michael,Fiala Mark,Kelley Sarah,etal.External validation of the simplified score to predict early relapse in multiple myeloma (S-ERMM) in the MMRF CoMMpass dataset[J]. Clinical Lymphoma, Myeloma and Leukemia,2022,22(S)20-21.
[ 2 0 ] C o w a n A n n i e , F e r r a r i F e d e r i c o , F r e e m a n Samuel,etal.The PANGEA model: dynamic modeling for personalized prediction of precursor disease progression to multiple myeloma[J]. Clinical Lymphoma,Myelomaand Leukemia,2022,22(S)：21-22.
